Founded in 2015, Tempus AI operates through two primary business segments: Diagnostics and Data and Applications. The Diagnostics segment, which generates the majority of the company's revenue, provides next-generation sequencing (NGS), PCR profiling, and molecular pathology tests for clinical use. The Data and Applications segment licenses de-identified clinical and molecular data to pharmaceutical and biotechnology companies to support drug discovery and clinical trials. Tempus primarily serves healthcare providers and life sciences companies in the United States. Its proprietary software applications, such as Hub and Lens, integrate into clinical workflows to deliver diagnostic results and research insights. The company's extensive library of paired clinical and molecular data supports its position in the precision medicine and genomic testing markets.
